Why Pfizer’s $10.5bn Innovent Biologics deal matters for the next wave of cancer medicines
Pfizer’s $10.5bn Innovent alliance deepens its oncology reset. Can early ADC and multispecific bets become global cancer drugs?
What Certis Oncology Intelligence reveals about the next phase of AI in cancer R&D
Certis Oncology has launched a new AI platform for translational oncology. Read what it could change for cancer drug development.